

SCIENTIFIC REPORTS



OPEN

A novel assay for screening inhibitors targeting HIV-1 integrase dimerization based on Ni-NTA magnetic agarose beads

Received: 12 January 2016

Accepted: 15 April 2016

Published: 03 May 2016

Dawei Zhang^{1,2}, Hongqiu He³, Mengmeng Liu¹, Zhixia Meng¹ & Shunxing Guo¹

Human immunodeficiency virus (HIV)-1 integrase (IN), which mediates integration of viral cDNA into the cellular chromosome, is a validated antiviral drug target. Three IN inhibitors, raltegravir, elvitegravir and dolutegravir, have been clinically approved since 2008. However, drug resistance have emerged in infected patients receiving treatment using these drugs which share the same mechanism of action and have a low genetic barrier for resistance. Therefore, there is an urgent need to develop drugs with novel mechanism. IN requires a precise and dynamic equilibrium between several oligomeric species for its activities. The modulation of the process which is termed as IN oligomerization, presents an interesting allosteric target for drug development. In this research, we developed a magnetic beads based approach to assay the IN dimerization. Then, using the assay we screened a library of 1000 Food and Drug Administration (FDA)-approved drugs for IN dimerization inhibitors and identified dexlansoprazole as a potential IN dimerization inhibitor. In conclusion, the assay presented here has been proven to be sensitive and specific for the detection of IN dimerization as well as for the identification of antiviral drugs targeting IN dimerization. Moreover, a FDA-approved proton-pump inhibitors, dexlansoprazole, was identified as a potential inhibitor for IN dimerization.

Retroviruses such as HIV-1 are characterized by integration of reverse-transcribed viral genome into the host cell chromosome¹. Viral integration, which is catalyzed by HIV-1 integrase (IN), comprises two spatially and temporally distinct steps, 3' processing and strand transfer². As a critical enzyme in the viral life cycle, IN is currently targeted by three FDA-approved drugs: raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG)³. All these drugs have the same mechanism of action: blocking the strand transfer activity of IN and are collectively termed as IN strand transfer inhibitors (INSTIs). However, significant cross-resistance has been observed within INSTIs in infected patients receiving treatment⁴⁻⁷. As a consequence, there is an urgent need to develop novel drugs with mechanism distinct from INSTIs to avoid existing and emerging multi-drug resistant HIV-1 strains.

IN is found as an equilibrium of monomers, dimers, tetramers, and even higher multimeric forms during integration, which is termed as IN oligomerization⁸. IN dimerization has been shown to be a plausible therapeutic target, for which several compounds and peptides have been found to display inhibitory activity⁹.

Recently, an AlphaScreen technology-based method for screening IN dimerization inhibitor was reported. However, this method has an obvious limitation: the requirement of expensive and sophisticated instruments which are not available to all laboratories. Moreover, a homogeneous time-resolved fluorescence based (HTRF) assay for detection of IN dimerization was reported and used to study the dynamics of IN dimerization¹¹. However, to the best of our knowledge, this assay has not been validated for high-throughput screening (HTS) or used for the screening of inhibitors targeting IN.

Drug repositioning is the process of identifying new uses for drugs outside the scope of their original medical indication¹². By exploiting existing knowledge of drugs, drug repositioning can offer a faster and cheaper

¹Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100193, China. ²Institute of Bioinformatics and Medical Engineering, School of Electrical and Information Engineering, Jiangsu University of Technology, Changzhou, 213001, China. ³Chongqing Center for Biomedicines and Medical Equipment, Chongqing Academy of Science and Technology, Chongqing, 401123, China. Correspondence and requests for materials should be addressed to Z.M. (email: mengzhixianj@163.com) or S.G. (email: sxguo1986@163.com)

approach than traditional drug discovery¹³. Drug repositioning has become an increasingly important part of the drug development landscape, with many pharmaceutical and biotech companies now having repositioning programs¹⁴. With lower costs, shorter development times and higher success rates, drug repositioning is also ideally suited for academia-based drug discovery¹⁴.

In this study, we developed a novel IN dimerization assay. Using the method, we undertook a drug repositioning screen to identify unknown IN dimerization inhibitory activity for known drugs. Besides, to provide confidence in our hits during screening, we implemented a counterscreen to eliminate molecules that interfere with the screening method itself.

Results and Discussion

Principle of the assay. The principle of the method is illustrated in Fig. 1A. In the assay, GST-tagged IN (yellow) is mixed with His₆-tagged IN (green) at the desired concentrations. Incubation at room temperature allows the formation of GST-IN/His₆-IN heterodimers as well as GST-IN and His₆-IN homodimers. Then, heterodimers will be captured by Ni²⁺-coated magnetic beads (red) through C-terminal His₆-tag and detected by alkaline phosphatase conjugated anti-GST antibody (dark red) through its N-terminal GST-tag. Whereas, neither of two kind of homodimers will be captured by Ni²⁺-coated magnetic beads and detected by alkaline phosphatase conjugated anti-GST antibody simultaneously. Hence, GST-IN/His₆-IN heterodimers will be detected as IN dimerization by the assay. The presence of modulating compounds in the assay will change the population of heterodimers or block the formation of them, resulting in an altered output signal and can be picked up by the spectrophotometer.

Assay development, performance evaluation and validation. This study aimed to establish a high-throughput assay for screening inhibitors targeting IN dimerization. To optimize the assay, titration experiments were performed. The optimal concentration of GST-IN and His₆-IN was determined to be 20 nM respectively. The primary antibody was prepared at a 1/4000 and secondary antibody at 1/5000. IN has the propensity to aggregate¹⁵, and theoretically IN tetramers and higher order oligomers containing both GST- and His₆-tags may also be captured by magnetic beads and detected by alkaline phosphatase conjugated anti-GST antibody in the assay. Generally, we cannot fully exclude that only IN dimers contribute to signal generation. However, in previous studies, the dissociation constants of IN dimers and tetramer were determined to be 67.8 pM and 22 μM^{11,16}. In their research, Tsiang *et al.* suggested that at the integrase concentrations used a maximum of 67.5 nM, the presence of integrase tetramer is negligible (0.068% of total integrase)¹¹. Accordingly, in our study, both GST-IN and His₆-IN were used at 20 nM, and the total concentration of IN was 40 nM which was less than 67.5 nM used by Tsiang *et al.* Therefore, in our assay, most of the IN existed in the form of dimer, the presence of IN tetramer and multimer should be omitted for simplicity.

Z' factor has been defined to evaluate suitability of an assay for HTS and signal-to-noise ratio (S/N), signal-to-background ratio (S/B) are widely used to indicate the quality of an assay^{17–19}. To test the suitability and quality of the assay, we measured the signal of all reactions under optimal reaction conditions. As shown in Fig. 1B, the negative controls in the absence of either GST-IN and His₆-IN or GST-IN or His₆-IN showed background readings measured as absorbance at 405 nm (A₄₀₅), lower than 0.11. Whereas, the IN dimerization gave a signal of 1.05. Accordingly, we determined the S/N, S/B and z' factor values of the assay and found that S/N, S/B and z' factor values was 295, 10 and 0.98 respectively, which all exceeded the minimum criteria (S/N > 10, S/B > 3 and z' > 0.5). Taken together, these values of statistical parameters confirmed that the assay developed was high sensitivity, specificity, and was suitable to be developed for HTS.

Peptide INH5 (ATDQAEHLKTAVQMAVFIHNYKA-CONH₂), which was previously reported as an inhibitor of IN dimerization, was used as a probe to test whether the HTS assay was effective for drug screening targeting IN dimerization²⁰. As shown in Fig. 1C, INH5 inhibited the IN dimerization with an IC₅₀ of 6.35 μM (95% confidence interval, 2.45 μM to 16.47 μM) which was comparable to previous experiment data 4.50 μM, indicating that the assay can robustly detect decreases in signal and is therefore effective and suitable for a HTS application¹⁰.

Identifying IN dimerization inhibitory activities for existing drugs. The optimized IN dimerization assay was used to screen a partial library of pharmacologically active compounds for inhibitors of IN dimerization. Compounds were screened as described in materials and methods section, with appropriate comparison controls included on each plate. Hits were scored as compounds that showed an inhibition ratio of the signal higher than 60% in the assays. The z', signal window (SW), and coefficient of variation (CV) of each plate were calculated and then compared with the minimum pass criteria (z' > 0.5, SW > 2.0, CV < 20%) to evaluate the quality of the HTS data. In a primary screening, at the concentration of 30 μM, 71 of the 1000 initial compounds were identified as hits, with a hit rate of 7.1% (Fig. 2A). All HTS campaigns in the primary screening exceeded the minimum criteria (z' > 0.5, SW > 2, and CV < 20%) (Fig. 2B–D), indicating that the results of the screening were reliable and could be used for further investigated. Then, 71 compounds screened out from the primary screening were re-screened and only one compound, dexlansoprazole (Fig. 2H), showed an excellent inhibitory rate of 87.17% (Fig. 2E). All HTS campaigns in the confirmatory screening also exceeded the minimum criteria (z' > 0.5, SW > 2, and CV < 20%), as such dexlansoprazole could be used for further study.

Non-specificity counterscreen validation. In a previous study, Schorpp *et al.* suggested that in a drug screening system using His₆-tag protein and nickel chelating beads, false-positive compounds could be identified²¹. This can be attributed to two possible reasons. One is hydrogen-bonded complexes formed between his-tagged protein and the compound would prevent immobilization of the protein on the beads surface. The other is the compound may act as nickel chelating agents and adsorb on the bead surface, thus preventing binding




Figure 1. Development of an *in vitro* screening method to identify IN dimerization inhibitors.

(A) The schemes depict the principle of the assay for IN dimerization. GST-tagged IN (yellow) is mixed with His₆-tagged IN (green) at the desired concentrations. Incubation at room temperature allows the formation of GST-IN/His₆-IN heterodimers as well as GST-IN and His₆-IN homodimers. Then, heterodimers will be captured by Ni²⁺-coated magnetic beads (red) through C-terminal His₆-tag and detected by alkaline phosphatase conjugated anti-GST antibody (dark red) through its N-terminal GST-tag. Changes in the population of heterodimers due to the presence of modulating compounds will result in an altered output signal and can be picked up. (B) Assay performance under optimal reaction conditions. Bars (A–C) represent signals produced from negative controls in the absence of either GST-IN and His₆-IN or GST-IN or His₆-IN respectively. Bar D represent signals produced from IN dimerization. (C) Inhibition of IN dimerization by peptide INH5. Error bars represent SD from 3 replicate values.




Figure 2. Results of the drug repositioning screen for IN dimerization inhibitors. (A) Scatterplots of the primary screening using the developed assay. Dashed line shows the 'hits' selection criteria (>60% disruption of a PPI complex); z' factor (B). SW (C) and CV (D) of each plate in the primary screening. Dashed lines show the minimum pass criteria ($z' > 0.5$, $S/N > 10$, $S/B > 3$, $SW > 2$, $CV < 20\%$). (E) Scatterplots of the confirmatory screening using the developed assay. Dashed line shows the 'hits' selection criteria (>60% disruption of a PPI complex). Z' factor, SW and CV of the confirmatory screening were 0.99, 6.19 and 10.8% respectively. (F) Counterscreen using His₆-GST protein was used to analyze the interference between dexlansoprazole and the assay system; (G) Dexlansoprazole identified in the screening exhibited a sigmoidal dose-dependent reduction of assay signal; (H) The chemical structure of dexlansoprazole.

of the proteins to the beads surface. Thus, in this study, a nonspecific counterscreen was performed to confirm dexamethasone is a specific inhibitor for IN dimerization rather than a false positive interfering with the assay system. In the counterscreen assay, His₆-GST protein was used, which could bind the Ni²⁺ coupling magnetic beads and be detected by GST antibody, generating an extremely strong signal. Any compound that interferes with beads or with the His₆-tag of His₆-GST protein will result in a decreased signal in the counterscreen assay. The results (Fig. 2F) showed that dexamethasone almost had no effect on the assay system, whereas displayed a dose-dependent effect on IN dimerization with an IC₅₀ value of 2.98 μM (Fig. 2G). All these results indicate that dexamethasone is a specific small molecular inhibitor for IN dimerization.

Conclusion

Based on Ni-NTA magnetic agarose beads, we have developed a highly sensitive and effective screening method to identify inhibitors of IN dimerization, and have successfully identified a FDA-approved drug dexamethasone as a potential small molecular inhibitor of IN dimerization, which may therefore serve as a lead compound for further optimization.

Methods

Construction of protein expression plasmids. The full-length HIV-1 IN coding sequence was amplified by PCR from pET28a-IN with a His₆ fusion tag on its N-terminus (conserved in our lab). Then, the amplified IN gene was subcloned into *Nco*I-*Xho*I sites of the vector pET28a to create the pET28a-IN for expression of recombinant C-terminal His₆-tagged IN protein (IN-His₆). In a similar manner, the amplified IN gene was subcloned into the *Bam*H I-*Sal*I sites of the vector pGEX-4T-1, creating pGEX-4T-IN for expression of recombinant N-terminal GST-tagged IN protein (GST-IN). The pGEX-4T-His₆ plasmid for expression of recombinant C-terminal His₆-tagged GST (His₆-GST) used for counterscreen was constructed by inserting the His₆-tag encoding sequences (CACCACCACCACCACCCTGA) to the *Bam*H I-*Sal*I sites of the plasmid pGEX-4T-1.

Recombinant proteins expression and purification. IN-His₆ was expressed and purified by affinity chromatography as previously described²². GST-IN and double-tagged GST-His₆ protein were produced using standard conditions as previously described¹⁰. The concentration of the all protein was determined by the Bradford assay with bovine serum albumin (BSA) as a standard. 12% SDS-PAGE was performed to determine the purity of the proteins.

The IN dimerization assay. The IN dimerization assay was developed based on Ni-NTA magnetic agarose beads. The assay was performed in 96-well NBS microplate in a final volume of 100 μl per well. Briefly, the assay works as follows. Compounds and proteins were diluted to 10× and 5× working solutions in the 1× assay buffer (25 mM tris-HCl, pH 7.4, 150 mM NaCl, 1 mM MgCl₂, 0.05% BSA[v/w]) respectively. First, 10 μl compound dilution, 50 μl 1× buffer, 20 μl each of protein dilutions were pipetted into the wells. The plate was sealed and left to incubate at 200 rpm for 3 h at room time (RT). Next, the 10 μl magnetic beads were added followed by incubating at 900 rpm for 30 min at RT. Then, the plate was placed on a magnetic concentrator, the supernatant was discarded, and the wells were washed 3 times with 200 μl wash buffer (50 mM sodium phosphate, pH 7.4, 150 mM NaCl, 0.005% Tween-20[v/v], 20 mM imidazole). The wells were incubated with 100 μl mouse anti-GST antibody diluted 1:4000 in antibody dilution buffer (50 mM sodium phosphate, pH 7.4, 150 mM NaCl, 0.005% Tween-20[v/v], 0.5%[w/v]BSA) at 900 rpm for 30 min at 37 °C, followed by washing three times as above. The wells were incubated with 100 μl rabbit anti-mouse IgG alkaline phosphatase conjugated antibody diluted 1:5000 in antibody dilution buffer at 900 rpm for 30 min at 37 °C, followed by washing three times as above. The color reaction was developed with 100 μl substrate buffer (10 mM diethanolamine, pH 9.8, 0.5 mM MgCl₂, 8 mM p-NPP) for 30 min at 37 °C. The plate was read at 405 nm with an Enspire multimode reader (PerkinElmer, USA). The reproducibility, signal stability, and robustness were determined for PPI assay to ensure it was HTS compatible. Also one IN dimerization inhibitor INH5 was used to validate the assay for HTS¹⁰.

Library screening for inhibitors of IN dimerization. In total, 1000 compounds were selected at random from ‘The Spectrum Collection’ purchased from National compound resource center. The library, which is composed of 2,320 compounds in 10 mM DMSO solution, lists primarily FDA-approved human therapeutic drugs, drug-like compounds, and natural products. Each compound was diluted in DMSO to reach a concentration of 300 μM, which was used as the 10× compound stock. In all screening campaigns, no-protein negative controls (including GST-IN was omitted or IN-His was omitted or both protein were omitted) and the positive control contained 10% v/v DMSO only. The negative and positive control with 8 replicates wells each located randomly among the 96 wells of each plate. The high-throughput assay was carried out in replicate in 96-well microplates as above.

A counterscreen was carried out as described above, replacing purified IN-His₆ and GST-IN with 20 nM His₆-tagged GST protein.

Data Analysis. The z' factor, signal-to-noise ratio (S/N), signal-to-background ratio (S/B), signal window (SW), and coefficient of variation (CV) were calculated and then compared with the minimum pass criteria (z' > 0.5, S/B > 3, SW > 2, CV < 20%)²¹. The ‘hits’ for PPI assays were classified as compounds that led to > 60% disruption of a PPI complex. All HTS data were processed using Excel (Microsoft Corp.) and visualized using Prism 5.0 (GraphPad Software).

References

1. Craigie, R. & Bushman, F. D. H. I. V. DNA integration. *Cold Spring Harb Perspect Med.* **2**, a006890 (2012).
2. Craigie, R. The molecular biology of HIV integrase. *Future Virol.* **7**, 679–89 (2012).
3. Hazuda, D. J. HIV integrase as a target for antiretroviral therapy. *Curr Opin HIV AIDS* **7**, 383–89 (2012).

4. Malet, I. *et al.* New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors. *J Antimicrob Chemother.* **69**, 2118–2112 (2014).
5. Sichtig, N. *et al.* Evolution of raltegravir resistance during therapy. *J Antimicrob Chemother.* **64**, 25–32 (2009).
6. Steigbigel, R. T. *et al.* Raltegravir with optimized background therapy for resistant HIV-1 infection. *N Engl J Med.* **359**, 339–54 (2008).
7. Métifiot, M. *et al.* Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. *AIDS* **25**, 1175–78 (2011).
8. Hayouka, Z. *et al.* Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium. *Proc Natl Acad Sci USA* **104**, 8316–21 (2007).
9. Feng, L., Larue, R. C., Slaughter, A., Kessler, J. J. & Kvaratskhelia, M. *Curr Top Microbiol Immunol* **389**, 1–27 (2015).
10. Demeulemeester, J., Tintori, C., Botta, M., Debyser, Z. & Christ, F. Development of an AlphaScreen-based HIV-1 integrase dimerization assay for discovery of novel allosteric inhibitors. *J Biomol Screen.* **17**, 618–28 (2012).
11. Tsiang, M. *et al.* Affinities between the binding partners of the HIV-1 integrase dimer-lens epithelium-derived growth factor (IN dimer-LEDGF) complex. *J Bio Chem.* **284**, 33580–99 (2009).
12. Krantz, A. Protein-site targeting. Diversification of the drug discovery process. *Nat Biotechnol.* **16**, 1294 (1998).
13. Jin, G. & Wong, S. T. C. Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. *Drug Discov Today* **19**, 637–44 (2014).
14. Ashburn, T. T. & Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. *Nat Rev Drug Discov.* **3**, 673–83 (2004).
15. Guiot, E. *et al.* Relationship between the Oligomeric Status of HIV-1 Integrase on DNA and Enzymatic Activity. *J Biol Chem.* **281**, 22707–19 (2006).
16. Jenkins, T. M., Engelman, A., Ghirlando, R. & Craigie, R. A. Soluble active mutant of HIV-1 integrase: involvement of both the core and carboxyl-terminal domains in multimerization. *J Biol Chem.* **271**, 7712–18 (1996).
17. Ingles, J. *et al.* High-throughput screening assays for the identification of chemical probes. *Nat Chem Biol.* **3**, 466–79 (2007).
18. Birmingham, A. *et al.* Statistical methods for analysis of high-throughput RNA interference screens. *Nat Methods* **6**, 569–75 (2009).
19. Zhang, J. H., Chung, T. D. Y. & Oldenburg, K. R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. *J Biomol Screen.* **4**, 67–73 (1999).
20. Maroun, R. G. *et al.* Peptide inhibitors of HIV-1 integrase dissociate the enzyme oligomers. *Biochemistry* **40**, 13840–48 (2001).
21. Schorpp, K. *et al.* Identification of small-molecule frequent hitters from AlphaScreen high-throughput screens. *J Biomol Screen.* **19**, 715–26 (2014).
22. He, H. Q. *et al.* A novel high-throughput format assay for HIV-1 integrase strand transfer reaction using magnetic beads. *Acta Pharmacol Sin.* **29**, 397–404 (2008).

Acknowledgements

This research was financially supported by the National Natural Science Foundation of China (Grant Nos. 31170016 and 81202438), Special Program for Applied Research on Super Computation of the NSFC-Guangdong Joint Fund (the second phase) and the Program for Innovative Research Team in IMPLAD (PIRTI-IT1302). The authors thank national compound resource center (Shanghai, China) for supplying the small compounds used in screening.

Author Contributions

D.Z., Z.M. and S.G. conceived and designed the experiments. D.Z. performed the experiments. D.Z. and M.L. analyzed the data. D.Z. and H.H. wrote the manuscript. All authors reviewed the manuscript.

Additional Information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Dawei, Z. *et al.* A novel assay for screening inhibitors targeting HIV-1 integrase dimerization based on Ni-NTA magnetic agarose beads. *Sci. Rep.* **6**, 25375; doi: 10.1038/srep25375 (2016).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>